PLURISTEM THERAPEUTICS INC (PSTI)

US72940R3003 - Common Stock

1  -0.03 (-2.91%)

After market: 1.03 +0.03 (+3%)

Fundamental Rating

2

Taking everything into account, PSTI scores 2 out of 10 in our fundamental rating. PSTI was compared to 587 industry peers in the Biotechnology industry. While PSTI seems to be doing ok healthwise, there are quite some concerns on its profitability. PSTI is valued expensive and it does not seem to be growing.



Quickly go to:

0

1. Profitability

1.1 Basic Checks

PSTI had negative earnings in the past year.
PSTI had negative earnings in 4 of the past 5 years.
PSTI had negative operating cash flow in 4 of the past 5 years.

1.2 Ratios

Industry RankSector Rank
ROA 59.22%
ROE 123.02%
ROIC 52.39%
ROA(3y)N/A
ROA(5y)N/A
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A

1.3 Margins

Industry RankSector Rank
OM -20665.22%
PM (TTM) 20373.91%
GM N/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A

More info and screens

4

2. Health

2.1 Basic Checks

With a Return on Invested Capital (ROIC) well above the Cost of Capital (WACC), PSTI is creating value.
PSTI has more shares outstanding than it did 1 year ago.
PSTI has a worse debt/assets ratio than last year.

2.2 Solvency

An Altman-Z score of 9.66 indicates that PSTI is not in any danger for bankruptcy at the moment.
PSTI has a Debt/Equity ratio of 0.60. This is a neutral value indicating PSTI is somewhat dependend on debt financing.
Industry RankSector Rank
Debt/Equity 0.6
Debt/FCF N/A
Altman-Z 9.66
ROIC/WACC5.53
WACC9.48%

2.3 Liquidity

PSTI has a Current Ratio of 8.22. This indicates that PSTI is financially healthy and has no problem in meeting its short term obligations.
A Quick Ratio of 8.22 indicates that PSTI has no problem at all paying its short term obligations.
Industry RankSector Rank
Current Ratio 8.22
Quick Ratio 8.22

More info and screens

1

3. Growth

3.1 Past

PSTI shows a strong growth in Earnings Per Share. In the last year, the EPS has been growing by 9.26%, which is quite good.
The Revenue for PSTI has decreased by -100.00% in the past year. This is quite bad
EPS 1Y (TTM)9.26%
EPS 3YN/A
EPS 5YN/A
EPS growth Q2Q35.42%
Revenue 1Y (TTM)-100%
Revenue growth 3YN/A
Revenue growth 5YN/A
Revenue growth Q2QN/A

3.2 Future

Based on estimates for the next years, PSTI will show a quite strong growth in Earnings Per Share. The EPS will grow by 14.41% on average per year.
No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
EPS Next Y40.89%
EPS Next 2Y2.16%
EPS Next 3Y25.38%
EPS Next 5Y14.41%
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A

3.3 Evolution

No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.

More info and screens

1

4. Valuation

4.1 Price/Earnings Ratio

The Price/Earnings Ratio is negative for PSTI. In the last year negative earnings were reported.
Besides the negative Price/Earnings Ratio, also the Forward Price/Earnings Ratio is negative for PSTI. No positive earnings are expected for the next year.
Industry RankSector Rank
PE N/A
Fwd PE N/A

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA -0.14

4.3 Compensation for Growth

A more expensive valuation may be justified as PSTI's earnings are expected to grow with 25.38% in the coming years.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y2.16%
EPS Next 3Y25.38%

More info and screens

0

5. Dividend

5.1 Amount

PSTI does not give a dividend.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

PLURISTEM THERAPEUTICS INC

NASDAQ:PSTI (7/25/2022, 7:17:24 PM)

After market: 1.03 +0.03 (+3%)

1

-0.03 (-2.91%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)
Earnings (Next)
Inst Owners
Inst Owner Change
Ins Owners
Ins Owner Change
Market Cap32.35M
Analysts
Price Target
Dividend
Industry RankSector Rank
Dividend Yield N/A
Dividend Growth(5Y)
DP
Div Incr Years
Div Non Decr Years
Ex-Date
Surprises & Revisions
EPS beat(2)
Avg EPS beat(2)
Min EPS beat(2)
Max EPS beat(2)
EPS beat(4)
Avg EPS beat(4)
Min EPS beat(4)
Max EPS beat(4)
EPS beat(8)
Avg EPS beat(8)
EPS beat(12)
Avg EPS beat(12)
EPS beat(16)
Avg EPS beat(16)
Revenue beat(2)
Avg Revenue beat(2)
Min Revenue beat(2)
Max Revenue beat(2)
Revenue beat(4)
Avg Revenue beat(4)
Min Revenue beat(4)
Max Revenue beat(4)
Revenue beat(8)
Avg Revenue beat(8)
Revenue beat(12)
Avg Revenue beat(12)
Revenue beat(16)
Avg Revenue beat(16)
PT rev (1m)
PT rev (3m)
EPS NQ rev (1m)
EPS NQ rev (3m)
EPS NY rev (1m)
EPS NY rev (3m)
Revenue NQ rev (1m)
Revenue NQ rev (3m)
Revenue NY rev (1m)
Revenue NY rev (3m)
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S
P/FCF
P/OCF
P/B
P/tB
EV/EBITDA
EPS(TTM)
EY
EPS(NY)
Fwd EY
FCF(TTM)
FCFY
OCF(TTM)
OCFY
SpS
BVpS
TBVpS
PEG (NY)N/A
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA 59.22%
ROE 123.02%
ROCE
ROIC
ROICexc
ROICexgc
OM -20665.22%
PM (TTM) 20373.91%
GM N/A
FCFM
ROA(3y)
ROA(5y)
ROE(3y)
ROE(5y)
ROIC(3y)
ROIC(5y)
ROICexc(3y)
ROICexc(5y)
ROICexgc(3y)
ROICexgc(5y)
ROCE(3y)
ROCE(5y)
ROICexcg growth 3Y
ROICexcg growth 5Y
ROICexc growth 3Y
ROICexc growth 5Y
OM growth 3Y
OM growth 5Y
PM growth 3Y
PM growth 5Y
GM growth 3Y
GM growth 5Y
F-Score
Asset Turnover0
Health
Industry RankSector Rank
Debt/Equity 0.6
Debt/FCF
Debt/EBITDA
Cap/Depr
Cap/Sales
Interest Coverage
Cash Conversion
Profit Quality
Current Ratio 8.22
Quick Ratio 8.22
Altman-Z
F-Score
WACC
ROIC/WACC
Cap/Depr(3y)
Cap/Depr(5y)
Cap/Sales(3y)
Cap/Sales(5y)
Profit Quality(3y)
Profit Quality(5y)
Growth
EPS 1Y (TTM)9.26%
EPS 3YN/A
EPS 5Y
EPS growth Q2Q
EPS Next Y40.89%
EPS Next 2Y
EPS Next 3Y
EPS Next 5Y
Revenue 1Y (TTM)-100%
Revenue growth 3YN/A
Revenue growth 5Y
Revenue growth Q2Q
Revenue Next Year
Revenue Next 2Y
Revenue Next 3Y
Revenue Next 5Y
EBIT growth 1Y
EBIT growth 3Y
EBIT growth 5Y
EBIT Next Year
EBIT Next 3Y
EBIT Next 5Y
FCF growth 1Y
FCF growth 3Y
FCF growth 5Y
OCF growth 1Y
OCF growth 3Y
OCF growth 5Y